{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T20:04:44Z","timestamp":1762459484756},"reference-count":39,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2017,3,28]],"date-time":"2017-03-28T00:00:00Z","timestamp":1490659200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0173168","type":"journal-article","created":{"date-parts":[[2017,3,28]],"date-time":"2017-03-28T19:00:14Z","timestamp":1490727614000},"page":"e0173168","update-policy":"http:\/\/dx.doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":5,"title":["Impact of lopinavir-ritonavir exposure in HIV-1 infected children and adolescents in Madrid, Spain during 2000-2014"],"prefix":"10.1371","volume":"12","author":[{"given":"Patricia","family":"Rojas S\u00e1nchez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis","family":"Prieto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Santiago","family":"Jim\u00e9nez De Ory","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisa","family":"Fern\u00e1ndez Cooke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Luisa","family":"Navarro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Tomas","family":"Ramos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c1frica","family":"Holgu\u00edn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Madrid Cohort of HIV-1 Infected Children and Adolescents Integrated in the Paediatric Branch of the Spanish National AIDS Network (CoRISPe)","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2017,3,28]]},"reference":[{"key":"ref1","unstructured":"Global report. UNAIDS report on the global AIDS epidemic 2013. http:\/\/www.unaids.org\/en\/media\/unaids\/contentassets\/documents\/epidemiology\/2014\/gr2014\/UNAIDS_Global_Report2014_en.pdf<\/ext-link>. Accessed September 2015."},{"key":"ref2","unstructured":"Guidelines for the Use of Antiretroviral Agents in Paediatric HIV Infection 2016. https:\/\/aidsinfo.nih.gov\/contentfiles\/lvguidelines\/paediatricguidelines.pdf<\/ext-link>"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1086\/521167","article-title":"Morbidity, mortality, and response to treatment by children in the United Kingdom and Ireland with perinatally acquired HIV infection during 1996\u20132006: planning for teenage and adult care","volume":"45","author":"A Judd","year":"2007","journal-title":"Clin Infect Dis"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1016\/S0140-6736(13)61409-9","article-title":"Early time-limited antiretroviral therapy versus deferred therapy in South African infants infected with HIV: results from the children with HIV early antiretroviral (CHER) randomised trial","volume":"382","author":"MF Cotton","year":"2013","journal-title":"Lancet"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"e151","DOI":"10.1016\/S2352-3018(15)00021-1","article-title":"Outcomes after viral load rebound on first-line antiretroviral therapy in HIV-infected children in the UK\/Ireland: an observational cohort study","volume":"4","author":"T Childs","year":"2015","journal-title":"Lancet HIV"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1586\/14787210.2015.1068117","article-title":"Tackling virological failure in HIV-infected children living in Africa","volume":"10","author":"MA Jenabian","year":"2015","journal-title":"Expert Rev Anti Infect Ther"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1093\/jac\/dku104","article-title":"Drug resistance in the HIV-1-infected paediatric population worldwide: a systematic review","volume":"69","author":"P Rojas S\u00e1nchez","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1111\/j.1468-1293.2009.00759.x","article-title":"PENTA 2009 guidelines for the use of antiretroviral therapy in pediatric HIV-1 infection","volume":"10","author":"S Welch","year":"2009","journal-title":"HIV Med"},{"key":"ref9","unstructured":"WHO. The use of antiretroviral drugs for treating and preventing HIV infection. Recommendations for a public health approach. Updated 2013. http:\/\/www.who.int\/hiv\/pub\/guidelines\/arv2013\/download\/en\/<\/ext-link>. Accessed October 2015."},{"key":"ref10","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1097\/QAD.0b013e32831c54e5","article-title":"HIV monotherapy with ritonavir-boosted protease inhibitors: a systematic review","volume":"23","author":"WF Bierman","year":"2009","journal-title":"AIDS"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"8528","DOI":"10.1038\/srep08528","article-title":"Efficacy and biological safety of lopinavir\/ritonavir based anti-retroviral therapy in HIV-1-infected patients: a meta-analysis of randomized controlled trials","volume":"5","author":"X Huang","year":"2015","journal-title":"Sci Rep"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1097\/01.inf.0000055061.97567.34","article-title":"Forty-eight-week evaluation of lopinavir\/ritonavir, a new protease inhibitor, in human immunodeficiency virus-infected children","volume":"22","author":"X S\u00e1ez-Llorens","year":"2003","journal-title":"Pediatr Infect Dis J"},{"key":"ref13","first-page":"59","article-title":"Novel strategies in the use of lopinavir\/ritonavir for the treatment of HIV infection in children","volume":"2","author":"BL Martinez","year":"2010","journal-title":"HIV AIDS"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1097\/INF.0b013e31821752d6","article-title":"Lopinavir\/ritonavir-based antiretroviral therapy in human immunodeficiency virus type 1-infected naive children: rare protease inhibitor resistance mutations but high lamivudine\/emtricitabine resistance at the time of virologic failure","volume":"30","author":"P Frange","year":"2011","journal-title":"Pediatr Infect Dis J"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1097\/QAD.0b013e32834403f6","article-title":"International Pediatric Adolescent Clinical Trials Group (IMPAACT) P1030 Team. Long-term outcomes for HIV-infected infants less than 6 months of age at initiation of lopinavir\/ritonavir combination antiretroviral therapy","volume":"25","author":"EG Chadwick","year":"2011","journal-title":"AIDS"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1056\/NEJMoa1000931","article-title":"Antiretroviral treatment for children with peripartum nevirapine exposure","volume":"363","author":"P Palumbo","year":"2010","journal-title":"N Engl J Med"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1056\/NEJMoa1113249","article-title":"Nevirapine versus ritonavir-boosted lopinavir for HIV-infected children","volume":"366","author":"A Violari","year":"2012","journal-title":"N Engl J Med"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1111\/j.1468-1293.2009.00728.x","article-title":"Boosted protease inhibitors as a therapeutic option in the treatment of HIV-infected children","volume":"10","author":"J Ramos","year":"2009","journal-title":"HIV Med"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1093\/cid\/civ110","article-title":"Choice of antiretroviral drugs for postexposure prophylaxis for children: a systematic review","volume":"60","author":"M Penazzato","year":"2015","journal-title":"Clin Infect Dis"},{"year":"2009","key":"ref20","article-title":"EMEA\/H\/C\/000368-II\/0090"},{"key":"ref21","unstructured":"Abbott laboratories. June 2010. Kaletra, highlights of prescribing information. http:\/\/www.rxabbott.com\/pdf\/kaletratabpi.pdf<\/ext-link>."},{"key":"ref22","doi-asserted-by":"crossref","first-page":"769","DOI":"10.2165\/00003495-200363080-00004","article-title":"Lopinavir\/ritonavir: a review of its use in the management of HIV infection","volume":"63","author":"R Cvetkovic","year":"2003","journal-title":"Drugs"},{"key":"ref23","first-page":"CD004772","article-title":"Optimization of antiretroviral therapy in HIV-infected children under 3 years of age","volume":"22","author":"M Penazzato","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1093\/jac\/dkr305","article-title":"Drug resistance prevalence and HIV-1 variant characterization in the naive and pretreated HIV-1-infected pediatric population in Madrid, Spain","volume":"66","author":"M de Mulder","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1089\/aid.2009.0122","article-title":"Pediatric HIV BioBank: a new role of the Spanish HIV BioBank in pediatric HIV research","volume":"26","author":"I Garc\u00eda-Merino","year":"2010","journal-title":"AIDS Res Hum Retroviruses"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"e82","DOI":"10.1097\/INF.0b013e3182117289","article-title":"Drug resistance prevalence in human immunodeficiency virus type 1 infected pediatric populations in Honduras and El Salvador during 1989\u20132009","volume":"30","author":"A Holgu\u00edn","year":"2011","journal-title":"Pediatr Infect Dis J"},{"key":"ref27","first-page":"642","article-title":"Update of the drug resistance mutations in HIV-1","volume":"22","author":"AM Wensing","year":"2014","journal-title":"Top Antivir Med"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3851\/IMP2973","article-title":"Description and consequences of prescribing off-label antiretrovirals in the Madrid Cohort of HIV-infected children over a quarter of a century (1988\u20132012)","volume":"21","author":"E Fern\u00e1ndez-Cooke","year":"2016","journal-title":"Ant Therapy"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"e93950","DOI":"10.1371\/journal.pone.0093950","article-title":"A comparison of supervised classification methods for the prediction of substrate type using multibeam acoustic and legacy grain-size data","volume":"9","author":"D Stephens","year":"2014","journal-title":"PLoS One"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"e1104","DOI":"10.1542\/peds.2014-0527","article-title":"PENPACT-1 (PENTA 9\/PACTG 390) Study Team. Using CD4 percentage and age to optimize pediatric antiretroviral therapy initiation","volume":"134","author":"DE Yin","year":"2014","journal-title":"Pediatrics"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S1473-3099(10)70313-3","article-title":"First-line antiretroviral therapy with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at higher versus low viral load in HIV-infected children: an open-label, randomised phase 2\/3 trial","volume":"11","author":"A Babiker","year":"2011","journal-title":"Lancet Infect Dis"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1097\/INF.0000000000000544","article-title":"Virologic failure among children taking lopinavir\/ritonavir-containing first-line antiretroviral therapy in South Africa","volume":"34","author":"T Meyers","year":"2015","journal-title":"Pediatr Infect Dis J"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1086\/380509","article-title":"Incidence of resistance in a double-blind study comparing lopinavir\/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine","volume":"189","author":"DJ Kempf","year":"2004","journal-title":"J Infect Dis"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1086\/588675","article-title":"Increased resilience to the development of drug resistance with modern boosted protease inhibitor-based highly active antiretroviral therapy","volume":"198","author":"VD Lima","year":"2008","journal-title":"J Infect Dis"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1097\/01.qai.0000137408.78031.37","article-title":"Predictive factors of virologic success in HIV-1-infected children treated with lopinavir\/ritonavir","volume":"37","author":"C Delaugerre","year":"2004","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1177\/135965350300800304","article-title":"Virological success of lopinavir\/ritonavir salvage regimen is affected by an increasing number of lopinavir\/ ritonavir-related mutations","volume":"8","author":"M Bongiovanni","year":"2003","journal-title":"Antivir Ther"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"e52155","DOI":"10.1371\/journal.pone.0052155","article-title":"High drug resistance prevalence among vertically HIV-infected patients transferred from paediatric care to adult units in Spain","volume":"7","author":"M de Mulder","year":"2012","journal-title":"Plos One"},{"issue":"605","key":"ref38","first-page":"e1","article-title":"Clinical and virologic follow-up in perinatally HIV-1-infected children and adolescents in Madrid with triple-class antiretroviral drug-resistant viruses","volume":"21","author":"P Rojas S\u00e1nchez","year":"2015","journal-title":"Clin Microbiol Infect"},{"key":"ref39","first-page":"32","article-title":"Recommendations of GESIDA\/Spanish AIDS Plan on antiretroviral therapy in adults infected by the human immunodeficiency virus","volume":"25","year":"2007","journal-title":"Enferm Infec Microbiol Clin"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0173168","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,27]],"date-time":"2022-07-27T00:08:26Z","timestamp":1658880506000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0173168"}},"subtitle":[],"editor":[{"given":"Carlo Federico","family":"Perno","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2017,3,28]]},"references-count":39,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2017,3,28]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0173168","relation":{},"ISSN":["1932-6203"],"issn-type":[{"type":"electronic","value":"1932-6203"}],"subject":[],"published":{"date-parts":[[2017,3,28]]}}}